6th Global Conference · World Pneumonia Day

Uniting the World
Against Pneumonia

Manila, Philippines · November 11, 2026

00
Days
00
Hours
00
Minutes
00
Seconds
40+
Countries Lighting Up Monuments
329
Monuments Turning Blue
17+
Global Speakers & Experts
6th
Edition of the Global Conference

In Partnership With

PneumoLight
Every Breath Counts
Philippine College of Chest Physicians
World Pneumonia Day

Relive The Movement

Conference Highlights

Look back at previous editions of the Global Conference for World Pneumonia Day and the community behind them.

5th Edition · AGEI Guatemala

5th Global Conference for World Pneumonia Day

4th Edition · Southeast Asia

4th Global Conference for World Pneumonia Day

Why This Matters

The Global Burden of Pneumonia

Awareness and education remain two of the most powerful tools we have in pneumonia prevention.

World Pneumonia Day — key global statistics

6th Global Conference · Manila 2026

Organizing Committee

The team coordinating this year's Global Conference for World Pneumonia Day.

Catia Cillóniz

Catia Cillóniz

Coordinator of the Worldwide Pneumonia Awareness Campaign

Rodolfo S. Pagcatipunan Jr.

Rodolfo S. Pagcatipunan Jr.

Vice-President, Research and Biotechnology, St. Luke's Medical Center

Guinevere Dy-Agra

Guinevere Dy-Agra

Institute of Pulmonary Medicine, St. Luke's Medical Center – Global City Taguig, Philippines

Dear Colleagues & Friends,

As Chairpersons of the 4th Global Conference for World Pneumonia Day 2024, it gives us great pleasure to invite you to join our event, which is part of the Worldwide Pneumonia Awareness Campaign-Pneumolight, with the support of the Philippine College of Physicians (PCP) in Manila, to be held on 9 November 2024.

Despite the global impact of the COVID-19 pandemic, pneumonia remains a neglected disease. Sadly, the 2021 Global Burden of Disease report showed that 2.1 million people died of pneumonia in that year; children under five years and adults over 70 continued to be the most vulnerable populations, with more than 500,000 and 1 million pneumonia-related deaths respectively. Another important problem is the impact of antimicrobial resistance (AMR); according to the 2019 GBD report, 1.27 million deaths were attributable to bacterial AMR in that year, and one in five deaths caused by AMR occurred in children under five years old. The 2019 GBD report identified Streptococcus pneumoniae as the most frequent pathogen causing pneumonia,
contributing to 16% of the deaths attributable to AMR.

Although great progress continues to be made, the worldwide burden of pneumonia remains huge. We need everyone to know about the disease and its impact on our health, and above all, we need to show that it can be prevented. Pneumonia must be recognized as a major global health problem. Until this recognition comes, we will continue our attempts to educate and prevent, because we know that education is prevention and prevention saves lives.

Working together, we can move the world because we know that if we fight, we can win!!!!

Yours sincerely,

Catia Cilloniz
Guinevere Dy-Agra
Rodolfo S. Pagcatipunan Jr

This will close in 0 seconds

This will close in 0 seconds

This will close in 0 seconds

Louis Bont, MD, PhD


Louis Bont, MD, PhD, is a Pediatric Infectiologist-Immunologist and the head of the Pediatric Department at the University Medical Center Utrecht, The Netherlands. He is the founding chairman of ReSViNET, an international respiratory syncytial virus (RSV) research consortium. His specific research interests include RSV pathogenesis and the burden of disease.

Dr. Bont's work focuses on unraveling the role of neutrophils, RSV-related mortality, and long-term airway disease following RSV infection. He is the lead investigator of the INFORM study, a large prospective global clinical virology study that aims to uncover the molecular epidemiology of RSV in over 2000 children. He also leads the RSV GOLD mortality registry, funded by the Bill and Melinda Gates Foundation.

His group collaborates with the World Health Organization on RSV surveillance and vaccine development. Dr. Bont’s research emphasizes clinical and translational mechanisms of disease and the identification of intervention targets for RSV bronchiolitis. He has been the lead author of over 300 publications in peer-reviewed medical journals.

Additionally, he founded the Training of Upcoming Leaders in Pediatric Science (TULIPS), a career training network for clinician scientists in the field of Child Health.

This will close in 0 seconds

This will close in 0 seconds